Lilly (Eli) revenue
Lilly (Eli)'s revenue was $65.18bn in fiscal 2025, up 44.7% on the year before. Since fiscal 2009 ($21.84bn) it has grown at a compound 7.1% a year. Over the last twelve months it was $86.46bn.
Revenue history
| Fiscal year | 2009Dec 2009 | 2010Dec 2010 | 2011Dec 2011 | 2012Dec 2012 | 2013Dec 2013 | 2014Dec 2014 | 2015Dec 2015 | 2016Dec 2016 | 2017Dec 2017 | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMSept 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 21.8 | 23.1 | 24.3 | 22.6 | 23.1 | 19.6 | 20.0 | 21.2 | 20.0 | 21.5 | 22.3 | 24.5 | 28.3 | 28.5 | 34.1 | 45.0 | 65.2 | 86.5 |
| Growth on the year before | — | +5.7% | +5.2% | −6.9% | +2.3% | −15.1% | +1.7% | +6.3% | −5.9% | +7.6% | +3.8% | +9.9% | +15.4% | +0.8% | +19.6% | +32.0% | +44.7% | — |
| Gross profit | — | — | — | — | — | — | — | 15.5 | 15.5 | 16.8 | 17.6 | 19.1 | 21.0 | 21.9 | 27.0 | 36.6 | 54.1 | 72.3 |
| Gross margin | — | — | — | — | — | — | — | 73.1% | 77.7% | 78.2% | 78.8% | 77.7% | 74.2% | 76.8% | 79.2% | 81.3% | 83.0% | 83.6% |
Where the revenue comes from
| Line of business | Revenue | YoY |
|---|---|---|
| Products | $61B | ▲ 49.6% |
| Collaboration and Other Revenue | $4.2B | ▼ 1.7% |
| Jardiance | $3.4B | ▲ 2.7% |
These categories overlap or exclude eliminations, so shares aren't shown.
| Region | Revenue | YoY |
|---|---|---|
| United States | $43.5B | ▲ 43.1% |
| Outside the US | $21.7B | ▲ 47.9% |
| Europe | $11.6B | ▲ 67.0% |
| Rest of World | $6.1B | ▲ 41.8% |
| Japan | $2.1B | ▲ 17.5% |
| China | $2B | ▲ 17.5% |
These categories overlap or exclude eliminations, so shares aren't shown.
From Lilly (Eli)'s 10-K filed February 12, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.
Revenue against peers
| Company | Revenue | Growth | 3-year growth a year |
|---|---|---|---|
| Lilly (Eli) | $86.46bn | 45.5% | 39.2% |
| Johnson & Johnson | $99.33bn | 7.8% | 5.9% |
| Merck & Co. | $66.57bn | 4.6% | 4.5% |
| Pfizer | $63.70bn | -0.2% | -7.0% |
| Astrazeneca PLC | $58.74bn | 8.6% | — |
| Bristol Myers Squibb | $50.03bn | 4.2% | 3.6% |
Compare with peers
- Johnson & Johnson revenue
- Merck & Co. revenue
- Pfizer revenue
- Astrazeneca PLC revenue
- Bristol Myers Squibb revenue
Head to head: JNJ vs LLYLLY vs MRKLLY vs PFE
More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies